

This is a provisional PDF only. Copyedited and fully formatted version will be made available soon.



CARDIOLOGY  
JOURNAL

ISSN: 1897-5593

e-ISSN: 1898-018X

## **Bivalirudin versus heparin in contemporary percutaneous coronary interventions for patients with acute coronary syndrome: a systematic review and meta-analysis**

**Authors:** Junyan Zhang, Zhongxiu Chen, Duolao Wang, Chen Li, Fangbo Luo, Yong He

**DOI:** 10.5603/cj.90956

**Article type:** Original Article

**Submitted:** 2022-07-12

**Accepted:** 2023-08-27

**Published online:** 2023-11-09

This article has been peer reviewed and published immediately upon acceptance. It is an open access article, which means that it can be downloaded, printed, and distributed freely, provided the work is properly cited. Articles in "Cardiology Journal" are listed in PubMed.

**Bivalirudin versus heparin in contemporary percutaneous coronary interventions for patients with acute coronary syndrome: a systematic review and meta-analysis**

Junyan Zhang et al., Bivalirudin versus heparin in PCI for acute coronary syndrome

Junyan Zhang<sup>1\*</sup>, Zhongxiu Chen<sup>1\*</sup>, Duolao Wang<sup>2</sup>, Chen Li<sup>1</sup>, Fangbo Luo<sup>3</sup>, Yong He<sup>1</sup>

<sup>1</sup>Department of Cardiology, West China Hospital of Sichuan University, Chengdu, China

<sup>2</sup>Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom

<sup>3</sup>Department of Rehabilitation, Community Health Center of Huaxing Wuhou District, Chengdu, Sichuan, China

Address for correspondence: Prof. Yong He, Department of Cardiology, West China Hospital of Sichuan University, 37 Guo Xue Xiang, Chengdu, Sichuan, 610041, China, tel: 028-85422353, e-mail: heyong\_huaxi@163.com

\*These authors contributed equally to this work.

**Abstract**

**Background:** Bivalirudin is associated with fewer major bleeding events than heparin in patients undergoing percutaneous coronary intervention (PCI), but confounding effects of concomitant glycoprotein IIb/IIIa inhibitors, routine femoral artery access, and less potent effects of clopidogrel limits meaningful comparisons. The present study is a systematic review and meta-analysis to compare bivalirudin to heparin in contemporary practice.

**Methods:** The Cochrane Library, PubMed, EMBASE, and Ovid MEDLINE databases were searched for relevant studies, including comparisons between bivalirudin and heparin in the current medical era from inception to December 23, 2021. Studies

reporting incidences of major adverse cardiac events (MACE) and net adverse clinical events (NACE) in patients undergoing PCI and meeting the inclusion criteria were retained. Data extraction was performed by three independent reviewers.

**Results:** The meta-analysis included 8 studies. Compared to heparin, bivalirudin during PCI was associated with a lower NACE risk, lower all-cause death, and similar MACE risk, with a pooled risk ratio of 0.82 (95% confidence interval [CI] 0.69–0.97,  $p = 0.02$ ), 0.83 (95% CI 0.74–0.94,  $p = 0.002$ ), and 0.93 (95% CI 0.78–1.10,  $p = 0.38$ ), respectively. Moreover, the reduction in NACE was mainly attributed to reduced bleeding (22% reduction in the risk of major bleeding, 95% CI 0.63–0.97,  $p = 0.03$ ).

**Conclusions:** These findings suggest that bivalirudin use during PCI reduced the risk of NACE and all-cause death but did not reduce the risk of MACE compared with heparin use in PCI. More studies specifically designed for anticoagulation strategies and a personalized anticoagulation regimen to comprehensively balance bleeding and ischemia risks are required.

**Keywords:** percutaneous coronary intervention, bivalirudin, heparin, contemporary practices, mortality

## **Introduction**

Primary percutaneous coronary intervention (PCI) is the optimum reperfusion strategy for patients presenting with acute myocardial infarction [1]. In the procedural phase, anticoagulant drugs combined with antiplatelet therapy are the accepted standard for preventing adverse ischemic events [2]. Bivalirudin is a direct thrombin inhibitor, working via the highly specific inhibition of thrombin. It can prolong activated clotting time to prevent thrombus formation during catheterization, and its inhibition of thrombin is reversible and short-lived [3, 4]. Earlier studies, such as the HORIZONS-AMI [5] and EUROMAX [6] trials, showed that anticoagulation with bivalirudin, compared to heparin plus glycoprotein IIb/IIIa inhibitors (GPI), reduced

the risk of death and bleeding but increased the incidence of acute stent thrombosis. Subsequently, the HEAT-PPCI trial [7] revealed that the bleeding risks of bivalirudin and heparin were comparable, but increased rates of acute stent thrombosis were observed in the bivalirudin group. In view of this, the BRIGHT trial [8] proposed the concept of the “antithrombosis empty window period” within 4 hours after PCI because of the short-term antithrombotic effect of bivalirudin and the delayed pharmacodynamic effects of clopidogrel and demonstrated that the use of bivalirudin with a median 3-hour post-procedure PCI-dose infusion resulted in a decrease in bleeding events, without significant differences in major adverse cardiac, cerebral events, or stent thrombosis.

However, significant advances have occurred in pharmacological therapy and PCI technology in the past 20 years. For example, the recent preferred use of radial-artery access and bailout GPI is associated with fewer major bleeding complications [9–11]. Moreover, the current recommended use of potent P2Y<sub>12</sub> inhibitors in patients with acute coronary syndrome (ACS) undergoing PCI and in chronic coronary syndrome patients with PCI and a high ischemia risk may also confound clinical outcomes [12–14]. According to the current practice, it is unclear whether bivalirudin performs better than heparin in PCI, especially in ACS patients. Thus, this study aimed to review the outcome of bivalirudin versus heparin use in PCI according to the current practice.

## **Methods**

### ***Search strategy***

This meta-analysis was performed in compliance with the PRISMA statement [15]. The study protocol was registered with PROSPERO (ID: CRD42022302633) at onset. PubMed, Embase, Ovid MEDLINE, and Cochrane Library databases were systematically searched for relevant studies from January 1, 2000 until December 23, 2021. The following medical subject heading terms and keywords were used to identify relevant articles: “bivalirudin” or “angiomax” or “hirulog” or “antithrombin”,

and “coronary stenting” or “percutaneous coronary intervention” or “PCI” or “angioplasty” or “coronary angioplasty” or “stents”. Both randomized controlled trials (RCTs) and cohort studies were included, excluding other study designs (cross-sectional and case-control studies). The references of studies were also checked for suitable articles. No language restriction was applied.

### ***Study selection***

Several assessments were performed, followed by the removal of duplicate articles after the initial screening. The titles and abstracts of relevant publications were further screened for suitability before full article retrieval. Additionally, meeting abstracts, editorials, and reviews were also checked and excluded from the analysis [16]. Studies included were those that: 1) compared bivalirudin with heparin in PCI; 2) were published in peer-reviewed journals with available full texts; 3) reported cardiovascular clinical outcomes; 4) reported the bailout use of GPI; 5) included the use of radial-artery access and potent P2Y<sub>12</sub> inhibitors; and 6) included mainly patients with ACS. Trials with the routine use of GPI, exclusive use of femoral-artery access, or clopidogrel were excluded. Three investigators (ZXC, JYZ, and FBL) independently reviewed all retrieved studies, and differences were resolved via consensus.

### ***Data extraction and quality assessment***

Study data, including the first author’s name, study design, location of study, sample size, clinical baseline characteristics, post-procedure infusion of bivalirudin, types of major adverse cardiac events (MACE), types of net adverse clinical events (NACE), frequency of patients in the bivalirudin and heparin groups, and incidence of mortality, were independently extracted by three investigators (JYZ, ZXC, CL). The definitions of MACE and NACE endpoints differed slightly between studies, but MACE basically included death, myocardial infarction (MI), and stroke, while NACE basically included MI, death from any cause, stroke, and major bleeding (Table 3).

The study quality was evaluated according to the Newcastle-Ottawa Quality scale. High-quality studies were defined as studies with a modified Newcastle-Ottawa score of  $\geq 5$  (maximum, 9).

### ***Statistical analysis***

Risk ratios of NACE, MACE, and particular events were estimated for each study between the bivalirudin and heparin groups. The heterogeneity of the effect measure was assessed by the Q and  $I^2$  statistics. A random-effects model (DerSimonian and Laird method) was applied if heterogeneity was detected ( $p < 0.10$  or  $I^2 \geq 25\%$ ); otherwise, a fixed-effects model (Mantel-Haenszel) was used. Subgroup analyses were conducted by the study design (randomized vs. cohort) and by bivalirudin infusion strategies during PCI (extended vs. non-extended). Sensitivity analyses, excluding one study at a time, were performed to clarify whether the results were due to a study with an extreme result. Publication bias was assessed using the Begg adjusted rank correlation test and Egger regression asymmetry test. A p-value of  $< 0.05$  was considered statistically significant. R version 4.1.2 software were used for the statistical analyses.

## **Results**

### ***Study selection***

636 publications were identified in PubMed, 617 publications in the Cochrane Library, and 838 publications in EMBASE and Ovid MEDLINE combined. Of these 2091 studies, 585 were duplicates. Eight of the remaining studies [6, 7, 17–22] met the inclusion criteria. Details of the search strategy are shown in Figure 1.

### ***Study characteristics and quality assessment***

Of the 8 included studies [6, 7, 17–22], 4 were randomized trials or prespecified subgroup analyses of randomized trials, whereas the others were retrospective or prospective cohort studies. Five of the included studies reported the NACE rates between the bivalirudin and heparin groups [6, 17–19, 21], while 7 reported MACE

rates [6, 7, 17–21]. Three of the included studies had subgroups or cohorts with extended post-procedure infusion of bivalirudin [6, 18, 21]. The mean risk-of-bias score in the Newcastle-Ottawa scale was 8.3, and all included studies were high quality (score > 5). For the quality assessment of RCTs, the scale mainly included the following: (1) generation of random sequence (selection bias); (2) concealment of distribution sequence (selection bias); (3) blind method for research object and implementer (implementation bias); (4) blind method for result evaluation (measurement bias); (5) incomplete result (loss of follow-up bias); (6) selective report (report bias); and (7) other bias. The general characteristics and definitions of outcome events in the included studies are summarized in Tables 1 to 3.

#### ***Risk of NACE in ACS patients undergoing PCI with bivalirudin vs. heparin***

Five of the studies with NACE as the outcome provided the number of patients with bivalirudin and heparin. The effects of bivalirudin were heterogeneous among these studies, with a pooled risk ratio of 0.82 (95% confidence interval [CI] 0.69–0.97,  $p = 0.03$ , Fig. 2). This suggests that patients with ACS undergoing PCI with bivalirudin had an 18% reduction in NACE risk compared to those using heparin during the procedure. This calculation also revealed a significant reduction in bleeding in the bivalirudin group compared to the heparin group, with a pooled risk ratio of 0.78 (Fig. 2). The subgroup of patients that received an extended bivalirudin infusion after PCI had a 27% reduction in NACE risk compared to those using heparin during PCI, with a pooled risk ratio of 0.73 (95% CI 0.55–0.98,  $p < 0.01$ , Fig. 3).

#### ***Risk of MACE in ACS patients undergoing PCI with bivalirudin vs. heparin***

Seven of the studies with MACE as the outcome provided the number of patients with bivalirudin or heparin during PCI. The effects of bivalirudin were heterogeneous among these studies, with a pooled risk ratio of 0.93 (95% CI 0.78–1.10,  $p = 0.38$ ). Patients with ACS undergoing PCI with bivalirudin showed a reduced risk of all-

cause mortality (Fig. 2) compared to those that used heparin during the procedure. However, the risk of cardiac death, MI, ischemic stroke, or stent thrombosis was similar between the two groups.

a subgroup analysis was performed of post-procedure bivalirudin infusions compared with heparin use during the procedure; bivalirudin demonstrated superior performance in the subgroup. Bivalirudin resulted in a decrease in NACE, greater decrease in major bleeding events, and lower risk of stent thrombosis (Fig. 3) compared with the group that did not use post-procedure bivalirudin infusion. In this subgroup, bivalirudin still reduced the risk of all-cause death and cardiac death (**Suppl. Fig. 1**) in patients undergoing PCI.

Furthermore, a subgroup analysis was performed of all RCT studies, which showed similar results as those above, including a decrease in NACE, without an increase in MACE or ST events (Suppl. Fig. 2).

### ***Stratified analysis and publication bias***

To explore the study heterogeneity, stratified analyses across several key study characteristics and clinical factors was performed. Examining RCTs and non-randomized studies separately showed similar conclusions compared to when both study types were combined. The Egger weighted regression and Begg rank correlation approaches found no evidence of publication bias in the reporting of the findings.

### **Discussion**

This systematic review and meta-analysis examined the effectiveness and safety of bivalirudin compared with heparin in contemporary PCI. According to available research, this is the first meta-analysis in the current medical era to assess this topic in this population. The present findings indicated that patients with ACS using bivalirudin during PCI had an 18% reduction in NACE risk compared to those using heparin. The reduction in NACE was mainly attributed to a reduction in bleeding. In addition, bivalirudin use in patients with ACS undergoing PCI did not show an



increased risk of MACE, including stent thrombosis, compared to those with heparin use during PCI. Moreover, compared with the subgroup of non-extended bivalirudin infusion, the extended infusion subgroup showed reduced all-cause death and cardiac death when the heparin group was used as a control, which was most likely due to the reduced incidence of ischemic cardiovascular events in the early postprocedural period.

These results demonstrate that using bivalirudin is feasible and favorable in patients with ACS undergoing PCI because it does not increase MACE while reducing bleeding events. However, the proportion of transradial access, potency of the P2Y<sub>12</sub> inhibitors administered, type of stent, and use of extended infusion after PCI varied among the included studies. These factors may lead to the fluctuation of the benefit difference between bivalirudin and heparin. Moreover, age, sex, combined hypertension, combined diabetes, renal insufficiency, and lesion characteristics may also contribute to the different outcomes for patients undergoing PCI with bivalirudin or heparin. Because these heterogenous factors may confound the results, more studies comparing bivalirudin and heparin alone in contemporary clinical practice are needed to illustrate the best anticoagulation regimens during PCI.

The main factors influencing the effect of periprocedural anticoagulation (bivalirudin or heparin) are discussed below.

### ***Bailout uses of GPI***

Bivalirudin is associated with fewer major bleeding events than heparin in patients undergoing PCI, but the confounding effect of concomitant GPI limits a meaningful comparison. Anantha-Narayanan et al. [23] performed a systematic review and meta-analysis to compare bivalirudin and heparin with and without adjunctive GPI in PCI. The study included 26 comparison groups (22 original studies and 4 subgroup analyses) with 53,364 patients and demonstrated that bivalirudin use is associated with a lower risk of major bleeding regardless of GPI use in the heparin arm. This persisted even after retaining studies with GPI use in the bivalirudin arm,

which was expected to bias the results towards the null. The prespecified analysis from the EUROMAX trial yielded a similar conclusion [24], which illustrates that bivalirudin reduces major bleeding compared to that using heparin therapy with bailout or routine GPI. The trial also indicated that routine GPI was not superior to bailout GPI regarding MACE or stent thrombosis. Bailout GPI is still a relevant choice currently because routine GPI use does not appreciably prevent ischemic events, such as MACE and stent thrombosis.

### ***Preferred transradial coronary interventions***

In the era of femoral artery access, several studies have shown that bivalirudin reduced the risk of bleeding in patients compared to that of heparin. However, it is unclear if the bleeding benefit of bivalirudin remains relevant considering the current increase in the use of transradial access. MacHaalany et al. [9] conducted research involving all-comers and demonstrated no additional benefit in terms of the bleeding risk with the use of bivalirudin compared with the use of heparin when PCI was performed via radial access. Moreover, a study conducted by Jovin et al. [20] with patients from the NCDR CathPCI database in whom PCI was predominantly performed via radial access showed that the risk of bleeding did not significantly differ between the bivalirudin and heparin groups. These results illustrated that the ability of bivalirudin to prevent bleeding is attenuated among patients that undergo PCI via transradial access [25]. However, with the bailout use of GPI and the emergence of the bivalirudin extended infusion strategy, the advantages of bivalirudin have been rediscovered. In a meta-analysis by Kheirim et al. [26] that included 10 RCTs with 16,328 patients for whom transradial access during PCI was exclusively performed, the use of bivalirudin was significantly associated with a reduction in short-term NACE (30-day) compared with heparin. Moreover, in the BRIGHT study, the majority of the patients (79%) had radial access, and bivalirudin still exhibited a bleeding benefit [8]. This finding is consistent with the results of the current study, which suggests that although theoretically possible, the advantage of bivalirudin in

reducing bleeding might be attenuated by transradial access, and it may still benefit patients in the contemporary medical setting.

### ***Post-procedure bivalirudin infusion***

In the present study, subgroup analysis showed that patients had better outcomes with respect to MACE, cardiac death, and stent thrombosis, when extended infusion strategy of bivalirudin was chosen. A single-center study by Frere et al. [27] prospectively enrolled 30 patients undergoing PCI for non-ST elevation ACS to investigate the antithrombotic efficacy of bivalirudin compared to unfractionated heparin during PCI. The study showed that an optimal inhibition of platelet reactivity was obtained 4 h after the PCI procedure. Another reason that patients with STEMI require a post-procedure PCI-dose of bivalirudin is that morphine and early gastrointestinal mucosal edema in STEMI inhibit the effect of P2Y<sub>12</sub> inhibitors [28]. Previous post hoc analyses have suggested that a prolonged infusion of high-dose bivalirudin after the procedure may prevent early stent thrombosis [16, 17]. As noted earlier, the BRIGHT trial proposed the concept of an “antithrombosis empty window period” within 4 hours after surgery because of the short antithrombotic effect of bivalirudin and the delayed pharmacodynamic effects of clopidogrel. The study demonstrated no significant differences in major adverse cardiac or cerebral events or stent thrombosis between the bivalirudin group with a median 3-h post-procedure PCI-dose infusion and those with heparin and GPI, while bivalirudin resulted in a decrease in bleeding events [8]. Moreover, Fahrni et al. [31] conducted a meta-analysis to compare the effect of prolonged PCI-dose bivalirudin infusion on clinical outcomes in patients undergoing primary PCI. The study included 6 RCTs comprising 17,294 patients and showed that prolonging the bivalirudin infusion at the PCI dose (1.75 mg/kg/h) for 3 h eliminated excess risk of acute stent thrombosis and maintained bleeding benefits [31]. Gargiulo et al. [21] reported outcomes of the MATRIX trial, where 3,610 patients were assigned to receive bivalirudin with or without prolonged post-PCI bivalirudin infusion. The results showed that a post-PCI

full-dose bivalirudin infusion was associated with improved outcomes when compared with a no or low-dose post-PCI infusion or heparin. These findings suggest that the infusion of bivalirudin after PCI is effective in reducing the incidence of stent thrombosis in the early postoperative period without increasing the patient's risk of bleeding. However, these studies mostly occurred in the era without potent P2Y<sub>12</sub> inhibitors, radial artery access, or routine GPI.

The BRIGHT-4 study is a randomized controlled clinical trial that aimed to compare the treatment of post-PCI bivalirudin high-dose infusion with heparin monotherapy. The study found that the treatment of post-PCI bivalirudin high-dose infusion can reduce the relative risk of primary endpoint events by 31% (3.06% vs. 4.39%,  $p = 0.0070$ ) compared with heparin monotherapy, including a 25% relative risk reduction in all-cause mortality (2.96% vs. 3.92%,  $p = 0.0420$ ) and a 79% relative risk reduction in major bleeding (0.17% vs. 0.80%,  $p = 0.0014$ ) within 30 days [32]. This study mainly used the potent P2Y<sub>12</sub> inhibitor ticagrelor, with the majority using the radial artery approach and without routine use of GPI, all of which suggest that the BRIGHT-4 study is more in line with contemporary clinical practices. Although the results of the BRIGHT-4 study were not yet published at the time of this meta-analysis, the conclusion of the present study is almost identical to the conclusion of the BRIGHT-4 study. Both studies suggest that bivalirudin has great value and prospects in today's clinical context. Therefore, based on the data included in this meta-analysis and the conclusion of the BRIGHT-4 study, it is believed herein, that in the next version of the guidelines, although the recommendation of bivalirudin may not replace heparin as the routine anticoagulant used in PCI due to the long-term experience with heparin and its simpler administration method, the recommendation level of bivalirudin may increase.

### ***Limitations of the study***

There were some limitations to the current study. First, the meta-analysis included both RCTs and cohort studies, which enhanced the heterogeneity of the studies, as

observational data are subject to possible observable and unobservable confounding factors. Second, definitions for MACE and NACE were not consistent across studies, and this might have resulted in measurement bias because some studies reported NACE with major bleeding alone, whereas some included only minor bleeding. Third, the proportions of GPI, novel P2Y<sub>12</sub> inhibitors, and radial access differed among studies, which also contributed to the heterogeneity of this study. Finally, because the BRIGHT-4 study was not published before December 2021, when the search was completed for this meta-analysis, the BRIGHT-4 study was not included in this study.

## **Conclusions**

Previous studies revealed that bivalirudin reduced the incidence of major bleeding in patients with ACS undergoing PCI compared to those receiving heparin, but it increased the risk of postoperative stent thrombosis. The meta-analysis, herein, revealed that bivalirudin is favorable in PCI in contemporary practice because it did not increase the risk of MACE and reduced the risks of NACE and all-cause death. In the contemporary medical era, with the use of new P2Y<sub>12</sub> antagonists and post-procedure bivalirudin infusion, the efficacy and safety of bivalirudin is reiterated. In conclusion, bivalirudin may be a better choice for patients with ACS during PCI compared with heparin alone in current medical practice.

## **Funding**

This study was funded by a grant from the Natural Science Foundation of China (grant number 82100282) and the 1.3.5 project for disciplines of excellence—Clinical Research Incubation Project, West China Hospital, Sichuan University (Grant/Award Number: 2021HXFH021).

**Conflict of interest:** None declared

## **References**

1. Garberich RF, Traverse JH, Claussen MT, et al. ST-elevation myocardial infarction diagnosed after hospital admission. *Circulation*. 2014; 129(11): 1225–1232, doi: [10.1161/CIRCULATIONAHA.113.005568](https://doi.org/10.1161/CIRCULATIONAHA.113.005568), indexed in Pubmed: [24389237](https://pubmed.ncbi.nlm.nih.gov/24389237/).
2. Agewall S, Antunes MJ, Bucciarelli-Ducci C, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation – Web Addenda. ; 8.
3. Mavrakanas TA, Chatzizisis YS. Bivalirudin in stable angina and acute coronary syndromes. *Pharmacol Ther*. 2015; 152: 1–10, doi: [10.1016/j.pharmthera.2015.04.003](https://doi.org/10.1016/j.pharmthera.2015.04.003), indexed in Pubmed: [25857452](https://pubmed.ncbi.nlm.nih.gov/25857452/).
4. Fiedler KA, Ndrepepa G, Schulz S, et al. Impact of bivalirudin on post-procedural epicardial blood flow, risk of stent thrombosis and mortality after percutaneous coronary intervention. *EuroIntervention*. 2016; 11(11): e1275–e1282, doi: [10.4244/EIJV11I11A249](https://doi.org/10.4244/EIJV11I11A249), indexed in Pubmed: [26865445](https://pubmed.ncbi.nlm.nih.gov/26865445/).
5. Mehran R, Lansky AJ, Witzenbichler B, et al. Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. *Lancet*. 2009; 374(9696): 1149–1159, doi: [10.1016/S0140-6736\(09\)61484-7](https://doi.org/10.1016/S0140-6736(09)61484-7), indexed in Pubmed: [19717185](https://pubmed.ncbi.nlm.nih.gov/19717185/).
6. Zeymer U, van 't Hof A, Adgey J, et al. Bivalirudin is superior to heparins alone with bailout GP IIb/IIIa inhibitors in patients with ST-segment elevation myocardial infarction transported emergently for primary percutaneous coronary intervention: a pre-specified analysis from the EUROMAX trial. *Eur Heart J*. 2014; 35(36): 2460–2467, doi: [10.1093/eurheartj/ehu214](https://doi.org/10.1093/eurheartj/ehu214), indexed in Pubmed: [24849104](https://pubmed.ncbi.nlm.nih.gov/24849104/).
7. Blake SR, Shahzad A, Kemp I, et al. Twelve-month mortality from the "How Effective are Antithrombotic Therapies in Primary Percutaneous Coronary Intervention (HEAT-PPCI) Trial". *Int J Cardiol*. 2020; 310: 37–42, doi: [10.1016/j.ijcard.2020.03.065](https://doi.org/10.1016/j.ijcard.2020.03.065), indexed in Pubmed: [32295716](https://pubmed.ncbi.nlm.nih.gov/32295716/).
8. Han Y, Guo J, Zheng Y, et al. Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction. *JAMA*. 2015; 313(13): 1336, doi: [10.1001/jama.2015.2323](https://doi.org/10.1001/jama.2015.2323).
9. MacHaalany J, Abdelaal E, Bataille Y, et al. Benefit of bivalirudin versus heparin after transradial and transfemoral percutaneous coronary intervention. *Am J Cardiol*. 2012; 110(12): 1742–1748, doi: [10.1016/j.amjcard.2012.07.043](https://doi.org/10.1016/j.amjcard.2012.07.043), indexed in Pubmed: [22980964](https://pubmed.ncbi.nlm.nih.gov/22980964/).

10. Wang H, Li Yi, Cong H, et al. Efficiency and safety of bivalirudin in patients undergoing emergency percutaneous coronary intervention via radial access: A subgroup analysis from the bivalirudin in acute myocardial infarction versus heparin and GPI plus heparin trial. *Catheter Cardiovasc Interv.* 2017; 89(7): 1157–1165, doi: [10.1002/ccd.26804](https://doi.org/10.1002/ccd.26804), indexed in Pubmed: [27677411](https://pubmed.ncbi.nlm.nih.gov/27677411/).
11. Anantha-Narayanan M, Anugula D, Gujjula NR, et al. Bivalirudin versus heparin in percutaneous coronary intervention-a systematic review and meta-analysis of randomized trials stratified by adjunctive glycoprotein IIb/IIIa strategy. *J Thorac Dis.* 2018; 10(6): 3341–3360, doi: [10.21037/jtd.2018.05.76](https://doi.org/10.21037/jtd.2018.05.76), indexed in Pubmed: [30069330](https://pubmed.ncbi.nlm.nih.gov/30069330/).
12. Bangalore S, Toklu B, Kotwal A, et al. Anticoagulant therapy during primary percutaneous coronary intervention for acute myocardial infarction: a meta-analysis of randomized trials in the era of stents and P2Y12 inhibitors. *BMJ.* 2014; 349: g6419, doi: [10.1136/bmj.g6419](https://doi.org/10.1136/bmj.g6419), indexed in Pubmed: [25389143](https://pubmed.ncbi.nlm.nih.gov/25389143/).
13. Rafique AM, Nayyar P, Wang TY, et al. Optimal P2Y12 Inhibitor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Network Meta-Analysis. *JACC Cardiovasc Interv.* 2016; 9(10): 1036–1046, doi: [10.1016/j.jcin.2016.02.013](https://doi.org/10.1016/j.jcin.2016.02.013), indexed in Pubmed: [27198684](https://pubmed.ncbi.nlm.nih.gov/27198684/).
14. Mehran R, Baber U, Sharma SK, et al. Ticagrelor with or without Aspirin in High-Risk Patients after PCI. *N Engl J Med.* 2019; 381(21): 2032–2042, doi: [10.1056/NEJMoa1908419](https://doi.org/10.1056/NEJMoa1908419), indexed in Pubmed: [31556978](https://pubmed.ncbi.nlm.nih.gov/31556978/).
15. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. *J Clin Epidemiol.* 2009; 62(10): e1–34, doi: [10.1016/j.jclinepi.2009.06.006](https://doi.org/10.1016/j.jclinepi.2009.06.006), indexed in Pubmed: [19631507](https://pubmed.ncbi.nlm.nih.gov/19631507/).
16. Chen Z, Li N, Wang J, et al. Association between mean platelet volume and major adverse cardiac events in percutaneous coronary interventions: a systematic review and meta-analysis. *Coron Artery Dis.* 2020; 31(8): 722–732, doi: [10.1097/MCA.0000000000000885](https://doi.org/10.1097/MCA.0000000000000885), indexed in Pubmed: [32310846](https://pubmed.ncbi.nlm.nih.gov/32310846/).
17. Erlinge D, Omerovic E, Fröbert O, et al. Bivalirudin versus Heparin Monotherapy in Myocardial Infarction. *N Engl J Med.* 2017; 377(12): 1132–1142, doi: [10.1056/nejmoa1706443](https://doi.org/10.1056/nejmoa1706443).
18. Zhang Y, Zhang Y, Liu Z, et al. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention in high-bleeding-risk patients with acute coronary syndrome in contemporary practice. *Biomed Pharmacother.*

- 2020; 130: 110758, doi: [10.1016/j.biopha.2020.110758](https://doi.org/10.1016/j.biopha.2020.110758), indexed in Pubmed: [34321166](https://pubmed.ncbi.nlm.nih.gov/34321166/).
19. Chen H, Yu X, Kong X, et al. Efficacy and safety of bivalirudin application during primary percutaneous coronary intervention in older patients with acute ST-segment elevation myocardial infarction. *J Int Med Res*. 2020; 48(9): 300060520947942, doi: [10.1177/0300060520947942](https://doi.org/10.1177/0300060520947942), indexed in Pubmed: [32985292](https://pubmed.ncbi.nlm.nih.gov/32985292/).
  20. Jovin IS, Shah RM, Patel DB, et al. Outcomes in patients undergoing primary percutaneous coronary intervention for st-segment elevation myocardial infarction via radial access anticoagulated with bivalirudin versus heparin: a report from the national cardiovascular data registry. *JACC Cardiovasc Interv*. 2017; 10(11): 1102–1111, doi: [10.1016/j.jcin.2017.03.021](https://doi.org/10.1016/j.jcin.2017.03.021), indexed in Pubmed: [28527778](https://pubmed.ncbi.nlm.nih.gov/28527778/).
  21. Valgimigli M, Frigoli E, Leonardi S, et al. Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial. *Lancet*. 2018; 392(10150): 835–848, doi: [10.1016/S0140-6736\(18\)31714-8](https://doi.org/10.1016/S0140-6736(18)31714-8), indexed in Pubmed: [30153988](https://pubmed.ncbi.nlm.nih.gov/30153988/).
  22. Grimfjård P, Erlinge D, Koul S, et al. Unfractionated heparin versus bivalirudin in patients undergoing primary percutaneous coronary intervention: a SWEDEHEART study. *EuroIntervention*. 2017; 12(16): 2009–2017, doi: [10.4244/EIJ-D-16-00884](https://doi.org/10.4244/EIJ-D-16-00884), indexed in Pubmed: [28044990](https://pubmed.ncbi.nlm.nih.gov/28044990/).
  23. Anantha-Narayanan M, Anugula D, Gujjula NR, et al. Bivalirudin versus heparin in percutaneous coronary intervention: systematic review and meta-analysis of randomized trials stratified by adjunctive glycoprotein IIb/IIIa strategy. *J Thorac Dis*. 2018; 10(6): 3341–3360, doi: [10.21037/jtd.2018.05.76](https://doi.org/10.21037/jtd.2018.05.76), indexed in Pubmed: [30069330](https://pubmed.ncbi.nlm.nih.gov/30069330/).
  24. Gutierrez A, Bhatt DL. Balancing the risks of stent thrombosis and major bleeding during primary percutaneous coronary intervention. *Eur Heart J*. 2014; 35(36): 2448–2451, doi: [10.1093/eurheartj/ehu223](https://doi.org/10.1093/eurheartj/ehu223), indexed in Pubmed: [24864080](https://pubmed.ncbi.nlm.nih.gov/24864080/).
  25. Perdoncin E, Seth M, Dixon S, et al. The comparative efficacy of bivalirudin is markedly attenuated by use of radial access: insights from Blue Cross Blue Shield of Michigan Cardiovascular Consortium. *Eur Heart J*. 2016; 37(24): 1902–1909, doi: [10.1093/eurheartj/ehv434](https://doi.org/10.1093/eurheartj/ehv434), indexed in Pubmed: [26377400](https://pubmed.ncbi.nlm.nih.gov/26377400/).



26. Kheiri B, Rao SV, Osman M, et al. Meta-analysis of bivalirudin versus heparin in transradial coronary interventions. *Catheter Cardiovasc Interv.* 2020; 96(6): 1240–1248, doi: [10.1002/ccd.28800](https://doi.org/10.1002/ccd.28800), indexed in Pubmed: [32091668](https://pubmed.ncbi.nlm.nih.gov/32091668/).
27. Frere C, Laine M, Lemesle G, et al. Antithrombotic efficacy of bivalirudin compared to unfractionated heparin during percutaneous coronary intervention for acute coronary syndrome. *Platelets.* 2019; 30(1): 105–111, doi: [10.1080/09537104.2017.1384541](https://doi.org/10.1080/09537104.2017.1384541), indexed in Pubmed: [29172822](https://pubmed.ncbi.nlm.nih.gov/29172822/).
28. Hamon M, Bonello L, Marso S, et al. Comparison of bivalirudin versus heparin(s) during percutaneous coronary interventions in patients receiving prasugrel: a propensity-matched study. *Clin Cardiol.* 2014; 37(1): 14–20, doi: [10.1002/clc.22208](https://doi.org/10.1002/clc.22208), indexed in Pubmed: [24114942](https://pubmed.ncbi.nlm.nih.gov/24114942/).
29. Valgimigli M, Frigoli E, Leonardi S, et al. Bivalirudin or Unfractionated Heparin in Acute Coronary Syndromes. *N Engl J Med.* 2015; 373(11): 997–1009, doi: [10.1056/nejmoa1507854](https://doi.org/10.1056/nejmoa1507854).
30. Clemmensen P, Wiberg S, van't Hof A, et al. Acute stent thrombosis after primary percutaneous coronary intervention. *JACC: Cardiovascular Interventions.* 2015; 8(1): 214–220, doi: [10.1016/j.jcin.2014.11.002](https://doi.org/10.1016/j.jcin.2014.11.002).
31. Fahrni G, Wolfrum M, De Maria GL, et al. Prolonged high-dose bivalirudin infusion reduces major bleeding without increasing stent thrombosis in patients undergoing primary percutaneous coronary intervention: novel insights from an updated meta-analysis. *J Am Heart Assoc.* 2016; 5(7), doi: [10.1161/JAHA.116.003515](https://doi.org/10.1161/JAHA.116.003515), indexed in Pubmed: [27451466](https://pubmed.ncbi.nlm.nih.gov/27451466/).
32. Li Yi, Liang Z, Qin L, et al. Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomised trial. *Lancet.* 2022; 400(10366): 1847–1857, doi: [10.1016/S0140-6736\(22\)01999-7](https://doi.org/10.1016/S0140-6736(22)01999-7), indexed in Pubmed: [36351459](https://pubmed.ncbi.nlm.nih.gov/36351459/).

**Table 1.** Baseline characteristics of the included studies.

<b>Research, Year</b>	<b>Study type</b>	<b>Quality score</b>	<b>Setting</b>	<b>Type of patients</b>	<b>Study design</b>	<b>Bolus after procedure</b>
Zhang, 2020	Cohort Study	7	The First Affiliated Hospital of Zhengzhou University	High-bleeding-risk ACS	Retrospective	Bivalirudin for up to 4 h after the procedure
Chen, 2020	Cohort Study	8	The First Affiliated Hospital of USTC	STEMI	Retrospective	
HEAT-PPCI, 2014	RCT	8	Liverpool Heart and Chest Hospital (UK)	STEMI	Prospective	
MATRIX, 2018	RCT	9	78 hospitals in Italy, the Netherlands, Spain, and Sweden	ACS	Prospective	Full dose for up to 4 h or at a reduced dose of 0.25 mg/kg/h for at least 6 h
VALIDATE - SWEDEHEART, 2017	RCT	9	Uppsala Clinical Research Center	STEMI and NSTEMI	Prospective	
NCDR CathPCI, 2017	Cohort Study	8	More than 1,800 sites across the United States	STEMI	Prospective	

SWEDEHE RT, 2016	Observational registry study	8	Swedish Coronary Angiography and Angioplasty Register (SCAAR)	STEMI	Prospective	
EUROMA X, 2014	Pre-specified analysis	9	Nine European countries	STEMI	Prospective	The infusion of bivalirudin should be continued for at least 4 h after PCI at a dose of be 0.25 mg/kg/h; however, continuation of the full dose (1.75 mg/kg/h) used during PCI was also permitted

ACS — acute coronary syndrome; DAPT — dual antiplatelet therapy; PCI — percutaneous coronary intervention; RCT — randomized controlled trial; STEMI — ST-segment elevation myocardial infarction

**Table 2.** Baseline characteristics of the included studies.

<b>Research, Year</b>	<b>Age, years</b>	<b>Male, n (%)</b>	<b>Hypertension, n (%)</b>	<b>Diabetes, n (%)</b>	<b>Dyslipidemia, n (%)</b>	<b>CKD, n (%)</b>	<b>Previous PCI, n (%)</b>
<b>Zhang, 2020</b>							
Bivalirudin (n = 361)	69.4 ± 10.1	213 (59.0%)	242 (67.0%)	130 (36.0%)	–	99 (27.4%)	92 (25.5%)
Heparin (n = 462)	66.4 ± 11.0	252 (54.5%)	302 (65.4%)	188 (40.7%)	–	133 (28.8%)	120 (26.0%)
<b>Chen, 2020</b>							
Bivalirudin (n = 412)	80.34 ± 4.54	257 (62.4%)	–	–	–	–	–
Heparin (n = 260)	78.73 ± 3.92	157 (60.4%)	–	–	–	–	–
<b>HEAT-PPCI, 2014</b>							
Bivalirudin (n = 905)	62.9 (53.7, 74.0)	647 (71.5%)	362 (40%)	114 (13%)	327 (37%)	/	76 (8%)
Heparin (n = 907)	63.6 (54.0, 73.8)	663 (73.1%)	388 (43%)	136 (15%)	342 (38%)	/	54 (6%)
<b>MATRIX, 2018</b>							
Bivalirudin (n = 3610)	65.4 ± 11.9	2731 (75.7%)	2264 (62.7%)	824 (22.8%)	1596 (44.2%)	48 (1.3%)	536 (14.8%)
Heparin (n = 3603)	65.4 ± 11.9	2764 (76.7%)	2222 (61.7%)	793 (22.0%)	1558 (43.2%)	47 (1.3%)	504 (14.0%)
<b>VALIDATESWEDEHEART, 2017</b>							
Bivalirudin (n = 3004)	68 (59,75)	2229 (74.2%)	1557 (51.8%)	491 (16.3%)	953 (31.7%)	/	456 (15.2%)

Heparin (n = 3002)	68 (60,75)	2177 (72.5%)	1548 (51.6%)	508 (16.9%)	936 (31.2%)	/	426 (14.2%)
<b>NCDR CathPCI, 2017</b>							
Bivalirudin (n = 29660)	60.3 ± 12.3	22,201 (74.9%)	19,456 (65.6%)	7,553 (25.5%)	17,009 (57.4%)	/	5,331 (18.0%)
Heparin (n = 37708)	60.4 ± 12.4	28,294 (75.0%)	24,707 (65.5%)	9,432 (25.0%)	21,742 (57.7%)	/	6,917 (18.3%)
<b>SWEDHEHERT/2016</b>							
Bivalirudin (n = 16891)	67.7 ± 12	11841 (70.1%)	7432(44%)	2415 (14.3%)	3547 (21%)	/	1351 (8%)
Heparin (n = 3724)	68.7 ± 12	2530 (68%)	1748(47%)	543 (14.6%)	893 (24%)	/	398 (10.7%)
<b>EUROMAX/2014</b>							
Bivalirudin (n = 1089)	61 (52, 71)	814 (21.9%)	459 (42.2%)	127 (11.7%)	398 (36.6%)	147 (14.7%)	97 (8.9%)
Heparin (n = 460)	62 (53, 73)	356 (77.4%)	243 (52.8%)	80 (17.4%)	417 (37.6%)	165 (16.5%)	51 (11.1%)

CKD — chronic kidney disease; PCI — percutaneous coronary intervention

**Table 3.** Baseline characteristics of the included studies.

Research, Year	Previous MI, n (%)	Current smoking, n (%)	Transradial access, n (%)	Potent P2Y12, n (%)	Outcome measurement	NACE	MACE or MACCE
<b>Zhang, 2020</b>					30 days	All-cause death, recurrent MI, ischemia-driven target vessel revascularization, stroke, and BARC 2–5 bleeding events	MI, death from any cause, or stroke
Bivalirudin (n = 361)	89 (24.7%)	104 (28.8%)	333 (92.2%)	229 (63.4%)			
Heparin (n = 462)	107 (23.2%)	128 (27.7%)	405 (87.7%)	315 (68.2%)			
<b>Chen, 2020</b>					1 year		All-cause death, recurrent MI, ischemia-driven target vessel revascularization, and stroke
Bivalirudin (n = 412)	32 (7.8%)	86 (20.9%)	347 (84.2%)	–			
Heparin (n = 260)	27 (10.4%)	41 (15.8%)	234 (90.0%)	–			
<b>HEAT-PPCI, 2014</b>					28 days	All-cause mortality, MI, stroke, or BARC 3 or 5†	All-cause mortality, cerebrovascular accident, reinfarction, or additional unplanned target
Bivalirudin (n = 905)	122(14%)	–	727 (80%)	801(89.0%)			
Heparin (n = 907)	93 (10%)	/	744 (82%)	819(91.0%)			

							lesion revascularization
<b>MATRIX, 2018</b>					1 year	Death from any cause, MI, or major bleeding	All-cause mortality, MI, or stroke
Bivalirudin (n = 3610)	530 (14.7%)	1307 (36.2%)	1676 (46.4%)	713 (19.8%)			
Heparin (n = 3603)	501 (13.9%)	1302 (36.1%)	1688 (46.8%)	690 (19.2%)			
<b>VALIDATESWEDEHEART, 2017</b>					30 days		
Bivalirudin (n = 3004)	490 (16.3%)	716 (23.8%)	2708 (90.1%)	2916 (97.1%)			
Heparin (n = 3002)	484 (16.1%)	710 (23.7%)	2716 (90.5%)	2927 (97.5%)			
<b>NCDR CathPCI, 2017</b>					30 days		Death, MI, stroke
Bivalirudin (n = 29660)	4,894 (16.5%)	–	29660 (100%)	14521 (47.7%)			
Heparin (n = 37708)	6,384 (16.9%)	–	37708 (100%)	15777 (51.1%)			
<b>SWEDEHERT, 2016</b>					1 year		Death, MI, stroke
Bivalirudin (n = 16891)	2010 (11.9%)	5219 (30.9%)	10641 (63%)	–			
Heparin (n = 3724)	617 (16.6%)	1038 (27.9%)	2269 (61%)	–			
<b>EUROMAX, 2014</b>					30 days	Death, MI, IDR, stroke, or major	Death, MI, IDR, or stroke
Bivalirudin (n = 1089)	80 (7.4%)	–	510 (47.7%)	578			

				(60.5%)		bleeding	
Heparin (n = 460)	48 (10.4%)	–	245 (54.1%)	194 (50.9%)			

BARC — Bleeding Academic Research Consortium; MACE — major adverse cardiac event; MI — myocardial infarction; NACE — net adverse cardiac event; ST — stent thrombosis

**Figure 1.** Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement (PRISMA) flow diagram of the study selection. PCI — percutaneous coronary intervention; DAPT — dual antiplatelet therapy; GPI — glycoprotein IIb/IIIa inhibitors; MACE — main adverse cardiac events.

**Figure 2.** Pooled relative risks of net adverse clinical events (NACE), all-cause death, main adverse cardiac events (MACE), and major bleeding in patients receiving bivalirudin vs. heparin during percutaneous coronary intervention. Major bleeding was defined as a bleeding event of the Bleeding Academic Research Consortium (BARC) type 2, 3, and 5 or BARC 3 and 5 according to the included studies.

**Figure 3.** Pooled relative risks of net adverse clinical events (NACE), stent thrombosis (ST), and major bleeding in patients receiving bivalirudin vs. heparin in the extended infusion subgroup. Major bleeding was defined as a bleeding event of the Bleeding Academic Research Consortium (BARC) type 2, 3, and 5 or BARC 3 and 5 according to the included studies.



2091 of records identified through database searching:  
Pubmed n= 636  
Ovid Medline/embase n= 838  
Cochrane Library n = 617

585 of records after duplicates removed


1506 of records screened

Case report n=33  
Conference/Editorial/Consensus/Protocol n=291  
Review/Meta-analysis n=276  
Non-bivalirudin/Non-PCI/Non-human n=351  
No MACE/ No potent P2Y12 n=232  
Planned GPI/Not compared with heparin n=166

157 of full-text articles assessed for eligibility

Planned GPI n=47  
No potent P2Y12 n=28  
No trans-radial access n=60  
Not enough data n=14

8 of studies included for meta-analysis



Major bleeding

